Mhlekude B, Postmus D, Stenzel S, Weiner 3rd J, Jansen J, Zapatero-Belinchon F
PLoS Pathog. 2023; 19(9):e1011657.
PMID: 37747932
PMC: 10629670.
DOI: 10.1371/journal.ppat.1011657.
Kazmierski J, Friedmann K, Postmus D, Emanuel J, Fischer C, Jansen J
Mol Syst Biol. 2022; 18(8):e10961.
PMID: 35975552
PMC: 9382356.
DOI: 10.15252/msb.202210961.
Natarelli L, Virgili F, Weber C
Int J Mol Sci. 2021; 22(22).
PMID: 34830125
PMC: 8620514.
DOI: 10.3390/ijms222212243.
Baldassarre A, Paolini A, Bruno S, Felli C, Tozzi A, Masotti A
Epigenomics. 2020; 12(15):1349-1361.
PMID: 32875809
PMC: 7466951.
DOI: 10.2217/epi-2020-0162.
Li Y, Wang H, Tang X, Fang S, Ma D, Du C
J Virol. 2020; 94(22).
PMID: 32847856
PMC: 7592233.
DOI: 10.1128/JVI.01283-20.
Cholesterol-conjugated peptide antivirals: a path to a rapid response to emerging viral diseases.
Pessi A
J Pept Sci. 2014; 21(5):379-86.
PMID: 25331523
PMC: 7167725.
DOI: 10.1002/psc.2706.
MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-α treatment.
de Wilde A, Raj V, Oudshoorn D, Bestebroer T, van Nieuwkoop S, Limpens R
J Gen Virol. 2013; 94(Pt 8):1749-1760.
PMID: 23620378
PMC: 3749523.
DOI: 10.1099/vir.0.052910-0.
A general strategy to endow natural fusion-protein-derived peptides with potent antiviral activity.
Pessi A, Langella A, Capito E, Ghezzi S, Vicenzi E, Poli G
PLoS One. 2012; 7(5):e36833.
PMID: 22666328
PMC: 3353973.
DOI: 10.1371/journal.pone.0036833.
Reverse genetics of SARS-related coronavirus using vaccinia virus-based recombination.
van den Worm S, Eriksson K, Zevenhoven J, Weber F, Zust R, Kuri T
PLoS One. 2012; 7(3):e32857.
PMID: 22412934
PMC: 3296753.
DOI: 10.1371/journal.pone.0032857.
Comparative pathogenesis of three human and zoonotic SARS-CoV strains in cynomolgus macaques.
Rockx B, Feldmann F, Brining D, Gardner D, LaCasse R, Kercher L
PLoS One. 2011; 6(4):e18558.
PMID: 21533129
PMC: 3080360.
DOI: 10.1371/journal.pone.0018558.
Identification and characterization of three novel small interference RNAs that effectively down-regulate the isolated nucleocapsid gene expression of SARS coronavirus.
Cao Y, Wang Y, Guo R, Yang F, Zhang Y, Wang S
Molecules. 2011; 16(2):1544-58.
PMID: 21317844
PMC: 6259856.
DOI: 10.3390/molecules16021544.
Phylogenetic perspectives on the epidemiology and origins of SARS and SARS-like coronaviruses.
Yip C, Hon C, Shi M, Lam T, Chow K, Zeng F
Infect Genet Evol. 2009; 9(6):1185-96.
PMID: 19800030
PMC: 7106296.
DOI: 10.1016/j.meegid.2009.09.015.
International research networks in viral structural proteomics: again, lessons from SARS.
Canard B, Joseph J, Kuhn P
Antiviral Res. 2007; 78(1):47-50.
PMID: 18054092
PMC: 2793675.
DOI: 10.1016/j.antiviral.2007.09.007.
Pathology and virus dispersion in cynomolgus monkeys experimentally infected with severe acute respiratory syndrome coronavirus via different inoculation routes.
Nagata N, Iwata N, Hasegawa H, Sato Y, Morikawa S, Saijo M
Int J Exp Pathol. 2007; 88(6):403-14.
PMID: 18039277
PMC: 2517337.
DOI: 10.1111/j.1365-2613.2007.00567.x.
Intranasal Protollin-formulated recombinant SARS S-protein elicits respiratory and serum neutralizing antibodies and protection in mice.
Hu M, Jones T, Kenney R, Barnard D, Burt D, Lowell G
Vaccine. 2007; 25(34):6334-40.
PMID: 17640780
PMC: 7115497.
DOI: 10.1016/j.vaccine.2007.06.017.
Heterologous MVA-S prime Ad5-S boost regimen induces high and persistent levels of neutralizing antibody response against SARS coronavirus.
Ba L, Yi C, Zhang L, Ho D, Chen Z
Appl Microbiol Biotechnol. 2007; 76(5):1131-6.
PMID: 17581748
PMC: 7079952.
DOI: 10.1007/s00253-007-1073-y.
Evolutionary insights into the ecology of coronaviruses.
Vijaykrishna D, Smith G, Zhang J, Peiris J, Chen H, Guan Y
J Virol. 2007; 81(8):4012-20.
PMID: 17267506
PMC: 1866124.
DOI: 10.1128/JVI.02605-06.
Naturally occurring anti-Escherichia coli protein antibodies in the sera of healthy humans cause analytical interference in a recombinant nucleocapsid protein-based enzyme-linked immunosorbent assay for serodiagnosis of severe acute respiratory....
Yip C, Hon C, Zeng F, Chow K, Chan K, Peiris J
Clin Vaccine Immunol. 2006; 14(1):99-101.
PMID: 17108287
PMC: 1797702.
DOI: 10.1128/CVI.00136-06.
Identifying epitopes responsible for neutralizing antibody and DC-SIGN binding on the spike glycoprotein of the severe acute respiratory syndrome coronavirus.
Shih Y, Chen C, Liu S, Chen K, Lee Y, Chao Y
J Virol. 2006; 80(21):10315-24.
PMID: 17041212
PMC: 1641789.
DOI: 10.1128/JVI.01138-06.
Quantitative comparison of the efficiency of antibodies against S1 and S2 subunit of SARS coronavirus spike protein in virus neutralization and blocking of receptor binding: implications for the functional roles of S2 subunit.
Zeng F, Hon C, Yip C, Law K, Yeung Y, Chan K
FEBS Lett. 2006; 580(24):5612-20.
PMID: 16989815
PMC: 7094555.
DOI: 10.1016/j.febslet.2006.08.085.